Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Change in Accured Expenses (2019 - 2025)

Korro Bio (KRRO) has disclosed Change in Accured Expenses for 6 consecutive years, with $189000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 126.4% year-over-year to $189000.0, compared with a TTM value of $477000.0 through Sep 2025, up 109.13%, and an annual FY2024 reading of -$4.0 million, down 412.52% over the prior year.
  • Change in Accured Expenses was $189000.0 for Q3 2025 at Korro Bio, down from $2.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.0 million in Q2 2025 and bottomed at -$5.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$181842.1, with a median of $357000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses skyrocketed 767.11% in 2023, then tumbled 351.92% in 2024.
  • Year by year, Change in Accured Expenses stood at $804000.0 in 2021, then crashed by 55.6% to $357000.0 in 2022, then plummeted by 228.85% to -$460000.0 in 2023, then soared by 273.04% to $796000.0 in 2024, then plummeted by 76.26% to $189000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for KRRO at $189000.0 in Q3 2025, $2.0 million in Q2 2025, and -$2.5 million in Q1 2025.